| Code | CSB-RA855470MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in US20150299325A1, specifically targeting CLEC4C (C-type lectin domain family 4 member C), also known as BDCA-2 or CD303. CLEC4C is a type II transmembrane receptor predominantly expressed on plasmacytoid dendritic cells (pDCs), where it functions as an endocytic receptor and plays a critical role in regulating innate immune responses. Upon ligand binding, CLEC4C triggers inhibitory signaling that suppresses TLR7/9-mediated interferon-alpha production by pDCs. This regulatory mechanism is particularly relevant in autoimmune diseases such as systemic lupus erythematosus and psoriasis, where aberrant pDC activation contributes to pathogenesis, as well as in cancer immunology where pDCs influence tumor microenvironments.
The reference antibody serves as a valuable research tool for investigating pDC biology, immune regulation, and CLEC4C-mediated signaling pathways. This biosimilar antibody enables researchers to explore the therapeutic potential of targeting CLEC4C in autoimmune disorders and to study pDC function in various disease contexts including viral infections and malignancies.
There are currently no reviews for this product.